--- title: "Dermatology Pharmaceuticals Industry" description: "190 SEC filers are classified under the Standard Industrial Classification code that describes the dermatology pharmaceuticals industry." canonical: https://www.getswoopr.com/stocks/industries/health-care/dermatology-pharmaceuticals/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Dermatology Pharmaceuticals Industry ## Direct Answer 190 SEC filers are classified under the Standard Industrial Classification code that describes the dermatology pharmaceuticals industry, and their latest annual reports show $454.1 billion of combined revenue and a median operating margin of -339.4%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics. ## Industry Overview Dermatology pharmaceutical companies develop and sell treatments for acne, psoriasis, eczema, rosacea and skin cancer. Topical products face generic competition, while newer biologics and oral drugs address larger markets. The first numbers to compare across companies here are prescription volume and net price, share of key categories and pipeline stage. ## Key Industry Metrics - **Prescription volume and net price**: Number of prescriptions and price received after rebates. Topical products often face price erosion from generics, so volume and price must be read together. - **Share of key categories**: Portion of prescriptions in categories such as psoriasis or eczema going to a company's drugs. It reflects competitiveness as new treatments arrive. - **Pipeline stage**: Where new candidates stand from early trials to approval. Newer biologics and oral drugs open larger markets, so late-stage progress matters. - **Patent timeline**: Dates when exclusivity ends. Topicals are exposed to generic entry sooner, so the timeline shows how long a product's revenue is protected. - **Marketing and detailing cost**: Selling expense including physician outreach and consumer advertising. It can drive prescriptions but reduces profit, so compare it with sales growth. ## Primary Macro Drivers - **Prevalence and patient awareness**: More awareness and diagnosis of skin conditions lead more people to seek treatment, which supports prescription volume. - **Payer coverage and step therapy**: Insurers often require patients to try cheaper drugs first, so coverage rules set how soon patients can get newer products and affect net price. - **New launches**: New drugs for eczema, psoriasis or acne can take share from older treatments, which shows in share of key categories. - **Direct-to-consumer demand**: Patients see ads and request drugs by name, which can lift volume but also raises marketing cost as a share of revenue. ## Major Risks - **Generic competition**: Cheaper copies of topical products take volume and net price once exclusivity ends; watch patent timeline and prescription share. - **Payer restrictions**: Step therapy and prior authorization slow new prescriptions and reduce net price; watch coverage decisions and rebate levels. - **Trial failures**: A failed study removes expected launches and the investment behind them; watch pipeline stage and readout dates. - **Safety labeling**: New warnings can limit use or make doctors cautious, lowering prescriptions; watch label updates and regulator communications. ## Industry Characteristics | Characteristic | Profile | | --- | --- | | Cyclicality | Defensive | | Capital Intensity | Medium | | Regulatory Intensity | High | | Industry Maturity | Mature | | Geographic Importance | U.S. / Global | ## Dermatology Pharmaceuticals Filers in the SEC Record 190 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification code 2834. Their latest fiscal years end between 2022 and 2026, and together they reported $454.1 billion of revenue. Median revenue growth over the prior year was 11.1%. Median operating margin was -339.4% and median net margin -202.0%. Median total liabilities were 40% of total assets, and 40 of 190 reported a profit in their latest year. | Company | Revenue | Growth | Operating margin | Net margin | Year | | --- | --- | --- | --- | --- | --- | | [Johnson & Johnson](https://www.getswoopr.com/stocks/companies/johnson-and-johnson/) | $94.2 billion | 6.0% | n/a | 28.5% | FY 2025 | | [Eli Lilly & Co](https://www.getswoopr.com/stocks/companies/eli-lilly/) | $65.2 billion | 44.7% | n/a | 31.7% | FY 2025 | | [Pfizer Inc](https://www.getswoopr.com/stocks/companies/pfizer/) | $62.6 billion | -1.6% | n/a | 12.4% | FY 2025 | | [Abbvie Inc.](https://www.getswoopr.com/stocks/companies/abbvie/) | $61.2 billion | 8.6% | 24.6% | 6.9% | FY 2025 | | [Bristol Myers Squibb Co](https://www.getswoopr.com/stocks/companies/bristol-myers-squibb/) | $48.2 billion | -0.2% | n/a | 14.6% | FY 2025 | | [Abbott Laboratories](https://www.getswoopr.com/stocks/companies/abbott-laboratories/) | $44.3 billion | 5.7% | 18.2% | 14.7% | FY 2025 | | [Viatris Inc](https://www.getswoopr.com/stocks/companies/viatris/) | $14.3 billion | -3.0% | -18.6% | -24.6% | FY 2025 | | [Vertex Pharmaceuticals Inc / Ma](https://www.getswoopr.com/stocks/companies/vertex-pharmaceuticals/) | $12.0 billion | 8.9% | 34.8% | 32.9% | FY 2025 | The 8 largest of 190 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code. ## Where to Go Next The Dermatology Pharmaceuticals guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company. ### More in Health Care - [Health Care sector overview](https://www.getswoopr.com/stocks/industries/health-care/) - [Diabetes Devices](https://www.getswoopr.com/stocks/industries/health-care/diabetes-devices/) - [Dental Service Organizations](https://www.getswoopr.com/stocks/industries/health-care/dental-service-organizations/) - [Diagnostic Devices](https://www.getswoopr.com/stocks/industries/health-care/diagnostic-devices/) - [Dental Equipment](https://www.getswoopr.com/stocks/industries/health-care/dental-equipment/) - [Diagnostic Laboratories](https://www.getswoopr.com/stocks/industries/health-care/diagnostic-laboratories/) - [Contract Research Organizations](https://www.getswoopr.com/stocks/industries/health-care/contract-research-organizations/) - [Diagnostics & Post-Acute Care](https://www.getswoopr.com/stocks/industries/health-care/diagnostics-and-post-acute-care/) - [Contract Development & Manufacturing Organizations](https://www.getswoopr.com/stocks/industries/health-care/contract-development-and-manufacturing-organizations/) ### Put it to work - [How to analyze a stock](https://www.getswoopr.com/stocks/how-to-analyze-a-stock/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) - [Company research](https://www.getswoopr.com/stocks/companies/) - [All industries](https://www.getswoopr.com/stocks/industries/) ## Frequently Asked Questions What are the main KPIs for the Dermatology Pharmaceuticals industry? Key performance indicators for the Dermatology Pharmaceuticals industry include: Prescription volume and net price, Share of key categories, Pipeline stage, Patent timeline, Marketing and detailing cost. Which matter most depends on the company's model, so compare them across several companies rather than relying on one. How cyclical is the Dermatology Pharmaceuticals industry? The Dermatology Pharmaceuticals industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions. What are the biggest risks in the Dermatology Pharmaceuticals industry? The primary risks for Dermatology Pharmaceuticals companies include: Generic competition, Payer restrictions, Trial failures, Safety labeling. Investors should assess each company's exposure to these factors and its track record of navigating them. **[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)** Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).